# A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

> **NCT06438263** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 231 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Rocatinlimab
- **DRUG:** Rocatinlimab

## Key facts

- **NCT ID:** NCT06438263
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-06
- **Primary completion:** 2025-05-03
- **Final completion:** 2025-07-02
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06438263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06438263, "A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06438263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*